Rhinovirus infection therapeutics currently exhibits a proliferating pipeline with 10 therapeutic candidates.
According to the research findings, most of the drug candidates are being developed as vaccine and administered by the intramuscular and intranasal route. The major advantage of vaccines includes they generate acquired immunity in the body against the rhinovirus infections. The building immunity by the vaccines resist the complications of infections.
Request for sample copy of this report at: https://www.pharmaproff.com/request-sample/1213
It has been observed that many pharmaceutical companies are leveraging new and improved technologies for the development of rhinovirus infection therapeutics. These technologies play an important role in the drug development; thereby, helping the companies to develop more specific and effective targeted therapies. For instance, Immune Dampening and Refocusing Technology developed by Biological Mimetics Inc., demonstrated a high potential in designing vaccines by minimizing limitations in the vaccine’s development. The technology focuses on identifying the epitopes that stimulate non-protective, strain-specific, or disease-enhancing immunity. The immune-mapping in technology helps in the identification of structure of antigens. This immune-based technology designed antigens can be introduced into the viral vectors or their recombinants subunits.
Some of the key players involved in the development of rhinovirus infection therapeutics in the late and mid stage include Romark L.C., Johnson & Johnson, Istari Oncology Inc., Merck & Co. Inc., and Vaxart Inc.
Rhinovirus Infection Therapeutics Pipeline Analysis
- By Phase
- By Molecule Type
- By Route of Administration
- By Company
This post was originally published on Financial Sector